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Clinical echinocandin resistance among Candida glabrata strains is increasing, especially in the United States. Antifungal sus-
ceptibility testing is considered mandatory to guide therapeutic decisions. However, these methodologies are not routinely per-
formed in the hospital setting due to their complexity and the time needed to obtain reliable results. Echinocandin failure in C.
glabrata is linked exclusively to Fks1p and Fks2p amino acid substitutions, and detection of such substitutions would serve as a
surrogate marker to identify resistant isolates. In this work, we report an inexpensive, simple, and quick classical PCR set able to
objectively detect the most commonmechanisms of echinocandin resistance in C. glabratawithin 4 h. The usefulness of this
assay was assessed using a blind collection of 50 C. glabrata strains, including 16 FKS1 and/or FKS2mutants.
Candida glabrata is a major agent of invasive candidiasis. It isconsidered the second-most-common Candida sp. isolated
from blood samples in the United States and northern and eastern
Europe and the third most common in the rest of the world (1–5).
Its high frequency is, at least in part, associated with antifungal
preexposure (6). Fluconazole resistance is common in C. glabrata,
and echinocandins are recommended as first-line therapy.
However, echinocandin resistance in C. glabrata is increasing
(with rates ranging from 1% to 3% worldwide), making suscepti-
bility testing mandatory to guide therapeutic decisions (1, 7–10).
The Clinical and Laboratory Standards Institute (CLSI) and the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) established reference broth microdilution methods
for Candida echinocandin susceptibility testing (11, 12). More-
over, the CLSI published revised interpretative guidelines in
December 2012 that showed good performance in identifying
echinocandin-resistant C. glabrata strains (7, 13). However, these
methods have several limitations, including (i) a time-consuming
and expensive methodology; (ii) the fact that standard echinocan-
din powders (indispensable for CLSI or EUCAST methods) are
not commercially available; (iii) caspofungin MIC interlaboratory
variability; (iv) overlapping susceptible and resistant populations;
and (v) the need for 24 h of processing to obtain results (5, 11,
12, 14).
Clinical echinocandin resistance in C. glabrata is linked with
substitutions in the hot spot regions of the Fks1p and Fks2p sub-
units of the -D-1,3-glucan synthase complex (the target of echi-
nocandins) (15–18). The detection of these FKS mutations has
been considered the most accurate way to predict an echinocandin
treatment failure (14, 18, 19). In an effort to improve the detection
of echinocandin-resistant C. glabrata isolates, we developed a set
of classical PCRs able to detect 10 of the most frequent mutations
associated with clinical echinocandin resistance in less than 4 h.
The sensitivity and specificity of the method were assessed using a
blind collection of C. glabrata clinical isolates comprising echino-
candin-resistant and -susceptible strains.
MATERIALS AND METHODS
Strains and blind study design. Fifty C. glabrata strains were used
throughout this work. All strains were isolated from patients with proven
invasive fungal disease (20). Nineteen strains were obtained from the
Public Health Research Institute (PHRI; Rutgers University, NJ), 20 from
the Mycology laboratory of the Ramos Mejia Hospital (Buenos Aires,
Argentina), and 11 from the Mycology and Molecular Diagnostics Labo-
ratory (LMDM) (Santa Fe, Argentina). Sixteen strains showed FKS1
and/or FKS2 hot spot region mutations (Table 1). C. glabrata ATCC
90030 was used as the wild-type control strain to validate the PCRs. C.
krusei ATCC 6258 and C. parapsilosis sensu stricto ATCC 22019 were used
as susceptibility testing control strains (11, 13). The isolates were identi-
fied as C. glabrata by conventional phenotypic methods and by sequenc-
ing of the 5.8S RNA gene and adjacent internal transcribed spacer 1 (ITS1)
and ITS2 regions (21, 22). The collection of strains was assembled at the
PHRI center, and blind code numbers were assigned. Also, a set of C.
glabrata strains with known FKS1 and/or FKS2 mutations were used to
develop and test the proposed methodology before confirming its utility
with the blind study.
Antifungals and susceptibility testing. Caspofungin (CSF; Merck &
Co. Inc., Rahway, NJ), anidulafungin (ANF; Pfizer, New York, NY), and
micafungin (MCF; Astellas Pharma USA Inc., Deerfield, IL) were ob-
tained as standard powder from their respective manufacturers. Echino-
candin susceptibility testing was performed in triplicate in accordance
with CLSI document M27-A3 and following the interpretive guidelines
published in the M27-S4 document (11, 13).
DNA isolation, PCR conditions, and primer and PCR set design. C.
glabrata genomic DNAs were extracted with phenol-chloroform method
(23) or with a Q-Biogene FastDNA kit (Q-Biogene). C. glabrata FKS1 and
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FKS2 genes with GenBank accession numbers XM_446406 and
XM_448401, respectively, were used for primer design. Two groups of
primers were used throughout this work. The primers in the first group
(PCR control primers), consisting of primer pair 1-1670F and 1-2225R
and primer pair 2-1619F and 2-2177R designed to specifically hybridize
FKS1 and FKS2, respectively, were used as an amplification control for
each of the five multiplex PCRs (Table 2). The second group of primers,
named the mutation detection primers, included five oligonucleotides
that were designed to detect the 10 most common mutations related with
echinocandin resistance. These primers align the FKS1 and FKS2 hot spot
1 regions and were named 1-F625, 1-S629, 1-D632, 2-F659, and 2-S663.
These primers were used in pairs with primers 1-1670F (1-S629 and
1-D632), 1-2225R (1-F625), 2-1619F (2-S663), and 2-2177R (2-F659).
PCR primers were designed by using the oligonucleotide design tool of the
IDT SciTools (Integrated DNA Technologies, Coralville, IA) and were
purchased from Integrated DNA Technologies (IDT-Biodynamics, Bue-
nos Aires, Argentina).
Amplifications were carried out in a 25-l volume of a mixture con-
taining 5 mM (NH4)2SO4, 5 mM KCl, 10 mM Tris-Cl (pH 8.8), 1 mM
MgSO4, 5 ng of bovine serum albumin, 0.1% Triton X-100, 125M each
TABLE 1 Comparison of results from classical PCR set, DNA sequencing, and in vitro susceptibility determinations of the C. glabrata strains
included in this study
Straina
Classical PCR set resultb DNA sequencing result MIC (g/ml)e
1-F625 1-S629 1-D632 2-F659 2-S663 Fks1pc Fks2pd ANF CSF MCF
WT (n 34)      WT WT 0.08 (S) 0.09 (S) 0.02 (S)
42997      F625S WT 2.00 2.00 0.50
5847      S629P WT 4.00 8.00 2.00
3169      D632E WT 2.00 2.00 2.00
LMDM 37      D632E WT 2.00 4.00 4.00
21900      D632G WT 1.00 4.00 0.06 (S)
42971      D632Y WT 4.00 4.00 1.00
31498      WT F659del 2.00 8.00 4.00
6183      WT F659S 4.00 8.00 4.00
M234      WT F659V 1.00 4.00 1.00
20.551.099      WT F659Y 1.00 2.00 0.12 (I)
3.830      WT S663P 2.00 8.00 1.00
37178      W645STOP S663P 4.00 8.00 8.00
M2798      WT S663P 8.00 8.00 8.00
20.593.033      W649STOP S663P 4.00 8.00 4.00
LMDM 34      WT S663P 2.00 8.00 2.00
M2791      WT S663F 4.00 4.00 4.00
a Includes 34 wild-type C. glabrata strains and 16 FKS1 and/or FKS2 mutants.
b Positive or negative signs indicate the presence or the absence of the corresponding PCR band in a electrophoresis gel.
c WT, wild type at hot spots. Fks1p hot spot 1 includes amino acids between 625 and 633 (625-FLILSLRDP-633).
d WT, wild type at hot spots. Fks2p hot spot 1 includes amino acids between 659 and 667 (659-FLILSLRDP-667).
e Data represent geometric mean values. MICs were obtained on three separate days. ANF, anidulafungin. CSF, caspofungin. MCF, micafungin. (S) or (I) indicates that the strain is
considered echinocandin susceptible or echinocandin intermediate, respectively (or is otherwise considered resistant), following the interpretative guidelines published in CLSI
document M27-S4 (13).
TABLE 2 Oligonucleotides primers used in this study
Oligonucleotidea Target gene Purpose(s)b 5=¡3= sequencec
1-1670F FKS1 FKS1 HS1 AfS and AC GTTGCTGCGGTCATGTTCTT
1-2225R FKS1 FKS1 HS1 AfS and AC GCGTTCCAGACTTGGGAAAT
2-1619F FKS2 FKS2 HS1 AfS and AC GAATGGTGGTTCGTTCCAAG
2-2177R FKS2 FKS2 HS1 sequencing and AC TGTTGCTTCTCAGACTTTCACC
1-F625F FKS1 Mutation detection CGCTGAATCATACTACTT
1-S629R FKS1 Mutation detection GATTGGATCTCTTGAGA
1-D632R FKS1 Mutation detection GACAAAATTCTGATTGGA
2-F659F FKS2 Mutation detection CTCTGAATCGTACTTCTT
2-S663R FKS2 Mutation detection GATAGGGTCTCTTAGAGA
1-1776F FKS1 FKS1 HS1 sequencing ACGTCGCTTCTCAAACCTTC
1-2008R FKS1 FKS1 HS1 sequencing CGGTAGCAATCATCAAACCC
2-1881F FKS2 FKS1 HS1 sequencing CGACGTTCAGCTTCAGAGTTT
2-2513R FKS2 FKS2 HS1 AfS CCAACAGAGAAGACAGTGTTGA
ITS1d rDNAe Molecular identification TCCGTAGGTGAACCTGCGG
ITS4d rDNA Molecular identification TCCTCCGCTTATTGATATGC
a F, sense; R, antisense.
b AfS, amplification for subsequent sequencing; AC, amplification control; HS1, hot spot 1.
c Nucleotides in bold show where a mutation could be present.
d From reference 24.
e rDNA, ribosomal DNA.
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dATP, dGTP, dCTP, and dTTP (Genbiotech, Buenos Aires, Argentina), a
0.5M concentration of each of the three primers, 1.25 U of Pegasus DNA
polymerase (PBL, Buenos Aires, Argentina), and 10 to 25 ng of C. glabrata
genomic DNA. Amplification was performed for one initial step of 2 min
at 94°C followed by 25 cycles of 30 s at 94°C, 30 s at 56°C, and 1 min at 72°C
and then a final cycle of 10 min at 72°C in an Applied Biosystems thermo-
cycler (Tecnolab-AB, Buenos Aires, Argentina). The PCR products were
analyzed by electrophoresis.
DNA sequencing. The C. glabrata FKS1 hot spot 1 region (nucleotide
[nt] 1776 to nt 2008),FKS2hot spot 1 region (nt 1881 to nt 2177), and 5.8S
RNA gene and adjacent internal transcribed spacer 1 (ITS1) and ITS2
regions were amplified and sequenced in both directions using the prim-
ers described in Table 2. For sequencing of the FKS1 and FKS2 hot spot 1
regions, primer pair 1-1670F and 1-2225R and primer pair 1-1619F and
1-2513R were used for PCR amplification, respectively. The purified frag-
ments were then subjected to sequencing using primers 1-1776F and
1-2008R for FKS1 and 2-1881F and 2-2177R for FKS2 (Table 2). In Ar-
gentina, DNA sequencing was performed using a BigDye Terminator cy-
cle sequencing ready-reaction system (Applied Biosystems, Buenos Aires,
Argentina) according to the manufacturer’s instructions. Sequence anal-
ysis was performed on an ABI Prism 310 DNA sequencer (Applied Bio-
systems) using the facilities available at Cromatida S.A. (Buenos Aires,
Argentina). In the PHRI Center, DNA sequencing was performed with a
CEQ dye terminator cycle sequencing QuickStart kit (Beckman Coulter,
Fullerton, CA) according to the manufacturer’s recommendations. Se-
quencing analyses were done with CEQ 8000 genetic analysis system soft-
ware (Beckman Coulter) and with the BioEdit sequence alignment editor
(Ibis Therapeutics, Carlsbad, CA).
RESULTS
Primer and PCR design for the detection of the molecular echi-
nocandin resistance mechanism in C. glabrata. The C. glabrata
FKS1 and FKS2 genes have high (73%) homology, with portions
with very low homology (lower than 50%) and others with the
highest homology (85% for the hot spot 1 regions of both genes)
(Fig. 1). For this reason, we designed two groups of primers
named PCR control primers and mutation detection primers
(both groups are described above). The primers of the first group
were designed to align the regions of lowest homology between the
genes (hot spot 1 external region) with dual objectives: (i) to give
the FKS1 or FKS2 gene specificity when used in combination with
the mutation detection primers and (ii) to use them as internal
controls for validation of the quality of DNA samples and the
absence of PCR inhibitors, since the presence of a mutation is
represented by a negative result in a PCR. On the other hand,
primers 1-F625, 1-S629, 1-D632, 2-F659, and 2-S663 were de-
FIG 1 (A) Representation of 1,000-nucleotide (nt) fragments of C. glabrata FKS genes, which include the hot spot 1 regions (white boxes). Filled arrows:
oligonucleotide primers included in the PCR control group used as the reaction control. Dashed arrows: primers designed to detect C. glabrata FKS1 and FKS2
mutations (mutation detection group). (B) Alignment of primers 1-F625F, 1-S629R, and 1-D632R with the wild-type (WT)FKS1 gene. (C) Alignment of primers
2-S663R and 2-F659F with the wild-type FKS2 gene and primer 2-F659F with the FKS2 gene with the deletion of three nucleotides (from T1995 to C1997) (gray
shading). Underlined nucleotides show the codons where the mutations are under cover by mutation detection primers. Boxes include the Fks1p and Fks2p hot
spot 1 regions.
Echinocandin Resistance Detection in C. glabrata
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signed specifically for priming FKS1 or FKS2 wild-type sequences,
considering that a 3= mismatch does not prime in a PCR under the
appropriate conditions of stringent annealing temperatures (Fig.
1). Furthermore, other reaction variables such as annealing tem-
peratures and MgSO4 and primer concentrations were taken into
consideration for PCR design to allow the use of one PCR pro-
gram irrespective of the primer set used. Under the PCR and re-
agent concentration conditions described above, all five PCRs
could be run at the same time and with the same program in the
thermocycler, showing excellent discrimination for both wild-
type and mutant alleles. Therefore, for detection of the substitu-
tion at Fks1p residues F625, S629, and D632, the multiplex PCRs
were performed using three primers per tube, including primers
1-1670F, 1-2225R, and 1-F625, primers 1-1670F, 1-2225R, and
1-S629, and primers 1-1670F, 1-2225R, and 1-D632, respectively.
These PCRs gave one 555-bp band in all the tubes and 369-bp,
263-bp, and 252-bp bands when the isolate was wild type at resi-
dues F625, S629, and D632 at Fks1p, respectively. On the other
hand, when a mutation is present in the codon that encodes any of
the three amino acid residues listed above, a unique 555-bp band
was observed after the electrophoresis (control PCR) (Fig. 2). The
detection of amino acid substitutions at residues F659 and S663 of
Fks2p was performed using a similar approach but with primers
2-1619F, 2-2177R, and 2-F659 and primers 2-1619F, 2-2177R,
and 2-S663, respectively. In these cases, for a wild-type isolate, two
bands (558 bp and 219 or 400 bp, respectively) were expected. For
an echinocandin mutant with a substitution at F659 or S663 resi-
dues, a single 558-bp band was obtained (Fig. 2).
Validation of the multiplex PCR sets. The utility of the PCR
sets was evaluated by using a blind collection of 50 C. glabrata
strains, including 16 echinocandin-resistant clinical isolates with
different amino acid substitutions in both Fksp proteins (Table 1).
Of the 50 isolates tested, 35 were considered wild-type strains by
the proposed methodology since the 5 PCR tubes presented two
bands in the electrophoresis. The rest were identified as FKS1 or
FKS2 mutants with an amino acid substitution at residues Fks1p-
F625 (n  1), Fks1p-S629 (n  1), Fks1p-D632 (n  4), Fks2p-
F659 (n  4), and Fks2p-S663 (n  5). A total of 49 of the 50
strains (98%) were correctly identified as echinocandin suscepti-
ble or resistant compared with the echinocandin susceptibility
testing results. Also, we found 98% concordance between our pro-
posed methodology and sequencing (Table 1). There was one false
result, comprising a FKS2 mutant, in which Fks2p showed a dele-
tion at the 659 residue (F659del). This deletion was not uncovered
by the 2-F659 primer because three nucleotides were deleted and
the nucleotide sequence where the primer was aligned was main-
tained (Fig. 2).
DISCUSSION
Prompt diagnosis and the correct treatment selection for invasive
Candida infections significantly reduce mortality (25). Echino-
candin drugs are now considered the best therapeutic option for
C. glabrata infections since these yeasts are less susceptible to flu-
conazole and amphotericin B than other Candida spp. (10). Re-
cent reports showed that the number of echinocandin-resistant
isolates is increasing, making essential an accurate assessment of
echinocandin susceptibility (7, 9). Whole-cell susceptibility test-
ing using a reference protocol takes at least 48 h (11, 12). However,
FIG 2 Electrophoresis of the PCR set resolved in a 1.5% agarose gel. The three primers used in each of the tubes are named above the images. Lane M, molecular
size marker. (A) PCRs designed to detect FKS1mutant. Lanes 2, 4, and 6,C. glabrataATCC 90030 (wild-type strain, echinocandin susceptible). Lane 3,C. glabrata
strain 42997 (Fks1p-F625S). Lane 5, strain 5847 (Fks1p-S629P). Lane 6, strain LMDM37 (Fks1p-D632E). Lane 7, C. glabrata 21900 (Fks1p-D632G). Lane 8,
isolate 42971 (Fks1p-D632Y). (B) Lanes 2 and 8, C. glabrata ATCC 90030 (echinocandin-susceptible wild-type strain). Lane 3, C. glabrata 3.830 (Fks2p-S663P).
Lane 4, strain 37178 (Fks2p-S663P). Lane 5, strain M2791 (Fks2p-S663F). Lane 6, isolate 20.593.033 (Fks2p-S663P). Lane 7, strain LMDM 34 (Fks2p-S663P).
Lane 9, strain 31498 (Fks2p-F659del). Lane 10, strain 6183 (Fks2p-F659S). Lane 11, strain M234 (Fks2p-F659V). Lane 12, isolate 20.551.099 (Fks2p-F659Y).
Dudiuk et al.
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outside the United States, most of the susceptibility testing is being
outsourced to reference laboratories due to the complexities of
these methodologies, increasing the time needed to obtain reliable
susceptibility data. To reduce this delay, we developed a simple set
of multiplex PCRs able to objectively classify a C. glabrata strain as
echinocandin susceptible or resistant in less than 4 h. The strict
linkage between FKS1 and FKS2 hot spot region mutations and
clinical echinocandin resistance provided the rationale for select-
ing the detection of these mutations as a surrogate marker for
resistance. Twenty-three different amino acid substitutions in
Fks1p and Fks2p hot spot regions were previously described (7, 8,
10, 15–17, 24, 26–31). However, 87.7% of the described clinically
echinocandin-resistant strains showed substitutions at the Fks1p-
F625 (2.46%), Fks1p-S629 (15.57%), Fks1p-D632 (5.74%),
Fks2p-F659 (17.21%), and Fks2p-S663 (46.72%) residues (per-
centages were obtained over a total of 122 strains, 63 included in
the cited reports plus 59 C. glabrata nonpublished echinocandin-
resistant strains held in the Perlin’s Echinocandin Resistance Ref-
erence Laboratory collection) (7, 8, 10, 15–17, 24, 26–31). More-
over, the strains harboring the most prevalent substitutions
showed the highest echinocandin MIC values (7, 8, 10, 15–17, 24,
26–31). These data led us to decide to include the described five
PCR assays to be able to detect the most common hot spot amino
acid substitutions linked with echinocandin resistance in C.
glabrata. In the blind study, we demonstrated that our set of PCRs
was able to uncover mutants harboring Fks1p-F625S, Fks1p-
S629P, Fks1p-D632G, Fks1p-D632E, Fks1p-D632Y, Fks2p-
F659S, Fks2p-F659V, Fks2p-F659L, Fks2p-S663P, and Fks2p-
S663F amino acid substitutions. Moreover, the designed primers
would also potentially uncover less-common mutations as Fks1p-
F625I (8) and Fks2p-F659Y (10, 24), since the primer’s 3= ends
would not hybridize these mutated sequences.
Recently, Pham et al. described a high-throughput micro-
sphere-based assay using the Luminex MagPix technology suit-
able to identify C. glabrata FKS mutants (19). This method would
be potentially used as a tool to evaluate a collection of strains in a
reference laboratory. The advantage of the methodology that we
are presenting is that it is based on the cheaper and commonly
available classical PCR methodology, making it suitable to be used
in a hospital setting for analyzing a few strains at a time. Moreover,
this new method is able to uncover FKS mutations more quickly
than other available molecular tools such as classical sequencing
methods with no need for special equipment.
The main limitation of the proposed set of PCRs is its inability
to detect the deletion of three nt at the codon which encoded the
F659 at the Fks2p. This false result would be considered a very
major error compared with whole-cell susceptibility testing since
our proposed methodology would thus classify a resistant strain as
susceptible. However, this molecular mechanism of echinocandin
resistance has been described in only few strains worldwide and it
is the least common substitution at this residue (8, 16, 19). Other
limitations of this methodology are its inability to detect newly
described mutations or other potential non-FKS-linked mecha-
nisms associated with echinocandin resistance and the possibility
of changes in epidemiology making the detection of the described
mutations useless. However, these potential drawbacks are shared
with any molecular method designed for the detection of mecha-
nisms of resistance (32–34). Nevertheless, this methodology is
suitable to be modified by adding or eliminating PCRs in order to
adapt it to detect emerging mechanisms of resistance.
In conclusion, we present an inexpensive, simple, and quick
molecular methodology able to objectively detect the most com-
mon mechanisms of echinocandin resistance in C. glabrata.
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